★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
◀ BACK TO FEED
NEWS★ LIFE SCIENCES / BIOTECHNOV 12, 2026

Orakl raises $34m to test cancer drugs against patient biology

Orakl Oncology combines patient-derived tumour models, clinical information and AI to study how cancer treatments perform.

Orakl raises $34m to test cancer drugs against patient biology

A digital model becomes more useful when it stays connected to real biology. Orakl Oncology is building that link for cancer drug development.

What happened

Orakl raised a $34m Series A, co-led by Norrsken VC and Singular, bringing total funding to $50m. It combines patient-derived tumour samples grown in the laboratory with clinical information and AI. The financing will expand its datasets, cancer coverage and teams in the US and UK.

Why it matters

Drug developers need to decide which treatments to advance and which patients to study. Laboratory models linked to patient information can help them investigate those questions earlier in development.

The bigger picture

The company’s assets extend beyond its algorithms. Generating biological data and maintaining hospital relationships are part of building an experimental platform that other researchers can use.

#ORAKL ONCOLOGY#DRUG DISCOVERY#CANCER